News

Baseline factors predict early response to multiple myeloma therapy


 

AT MHM 2015

References

CHICAGO – Age and the results of select baseline lab measures reflected early response to initial therapy in a review of 1,304 newly diagnosed patients with symptomatic multiple myeloma.

Characteristics associated with increased odds of achieving very good partial response or better (VGPR+) within four cycles of treatment in the study participants, who were seen between 2001 and 2013, were absolute free light chain difference of more than 175 mg/dL (odds ratio, 2.38), age less than 75 years at diagnosis (OR, 2.18), hemoglobin concentration less than 10/12.5 (OR, 1.68), and IgA vs. IgG serum heavy chain secretion (OR, 1.66), Dr. Moritz Binder of the Mayo Clinic, Rochester, Minn., reported in a poster at the American Society of Hematology Meeting on Hematologic Malignancies.

Dr. Moritz Binder

Dr. Moritz Binder

In patients receiving proteasome inhibitors, better response was associated with creatinine concentrations greater than 1.5 mg/dL (OR, 3.83), calcium concentration less than 9.0 mg/dL (OR, 3.37), and greater absolute free light chain difference greater than 175 mg/dL (OR, 2.50), Dr. Binder noted.

High-risk cytogenetic features, conversely, were not associated with treatment response, he said.

The findings are important because the initial response to therapy in newly diagnosed disease can have an effect on long-term outcomes; achieving at least a VGPR to initial treatment can improve progression-free and overall survival. Further, novel agents and risk-adapted treatment strategies now in use have improved response rates and overall survival, Dr. Binder said, adding that it has been unclear, however, whether baseline laboratory parameters could predict the likelihood of early, deep response to initial therapy.

“The ability to predict the likelihood of response to the current therapies can have implications for the treatment approaches in NDMM,” he wrote.

In this study, 288 patients achieved VGPR+ after 4 months, and those patients had a decreased risk of subsequent mortality (hazard ratio, 0.69). This remained true after adjusting for sex, age, International Staging System stage, bone marrow plasma cell involvement, lactate dehydrogenase concentration, initial treatment regimen group, and hematopoietic stem cell transplantation during the disease course (HR, 0.68), he said.

The three most common regimens with immunomodulators that were used in the cohort were lenalidomide-dexamethasone, thalidomide-dexamethasone, and cyclophosphamide-lenalidomide-dexamethasone, and the three most common regimens with proteasome inhibitors were bortezomib-cyclophosphamide-dexamethasone, bortezomib-lenalidomide-dexamethasone, and bortezomib-dexamethasone.

Dr. Binder reported receiving research funding from ASH. Coauthors reported receiving research funding from Celgene, Janssen, Millennium, and Pfizer, and/or serving in an advisory role for Pfizer.

sworcester@frontlinemedcom.com

Recommended Reading

Data support subcutaneous bortezomib in multiple myeloma
MDedge Hematology and Oncology
Aberrant miRNA levels may reflect progression to multiple myeloma
MDedge Hematology and Oncology
New guidelines address multiple myeloma–related complications
MDedge Hematology and Oncology
CHMP grants accelerated assessment for MM drug
MDedge Hematology and Oncology
Group calls for more investment in radiotherapy
MDedge Hematology and Oncology
Signature may predict progression to MM
MDedge Hematology and Oncology
CHMP recommends carfilzomib for MM
MDedge Hematology and Oncology
Combo demonstrates potential in MM
MDedge Hematology and Oncology
Variations in blood cancer survival across Europe
MDedge Hematology and Oncology
mAb produces ‘encouraging’ results in MM
MDedge Hematology and Oncology